<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04346537</url>
  </required_header>
  <id_info>
    <org_study_id>92424682</org_study_id>
    <nct_id>NCT04346537</nct_id>
  </id_info>
  <brief_title>INGEVITY+ Active Fixation Pace/Sense Lead Clinical Study</brief_title>
  <official_title>INGEVITY+ Active Fixation Pace/Sense Lead Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is it to confirm the safety and effectiveness of the INGEVITY+
      Active Fixation Pace/Sense Lead.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety: Lead-related Complication-Free Rate</measure>
    <time_frame>Lead Implant through 3-Months Post-Implant</time_frame>
    <description>Lead-related Complication-Free Rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Effectiveness: Pacing Capture Threshold Responder Rate</measure>
    <time_frame>At 3-Months Post-Implant</time_frame>
    <description>Pacing Capture Threshold Responder Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Effectiveness: Sensed Amplitude in mV</measure>
    <time_frame>At 3-Months Post-Implant</time_frame>
    <description>Sensed Amplitude in mV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Effectiveness: Pacing Impedance in Ohms</measure>
    <time_frame>At 3-Months Post-Implant</time_frame>
    <description>Pacing Impedance in Ohms</description>
  </secondary_outcome>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Bradycardia</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>INGEVITY+ Lead</intervention_name>
    <description>The INGEVITY+ lead is indicated for chronic pacing and sensing in the right atrium and/or right ventricle when used with a compatible pulse generator.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be selected from the investigator's general patient population indicated for
        dual-chamber pacemaker or CRT-P implantation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is willing and capable of providing informed consent

          2. Subject is intended to undergo initial (de novo) pacing system implant using INGEVITY+
             Leads in the Right Atrium (RA) and Right Ventricle (RV) and a Boston Scientific pulse
             generator

          3. Subject meets an indication for a Boston Scientific Pacemaker or CRT-P device per
             product labeling (Physician's Technical Manual)

          4. Willing and capable of participating in all testing/visits associated with this
             clinical study at an approved clinical study center and at the intervals defined by
             this protocol

          5. Age 18 or above, or of legal age to give informed consent specific to state and
             national law

        Exclusion Criteria:

          1. Known or suspected sensitivity to dexamethasone acetate (DXA)

          2. Has a mechanical tricuspid heart valve

          3. Women of childbearing potential who are or might be pregnant at the time of study
             enrollment or INGEVITY+ Lead implant (method of assessment upon physician's
             discretion)

          4. Currently requiring hemo- or peritoneal dialysis

          5. Subject has or has had implanted any pacing or ICD system, including subcutaneous,
             transvenous or leadless systems

          6. Intended to receive a single chamber device

          7. Documented history of permanent or persistent AF

          8. Currently on an active organ transplant list

          9. Documented life expectancy of less than 12 months

         10. Enrolled in any other concurrent study unless prior approval is received from the
             Sponsor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Devi Nair, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nair Associates, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gena Kantor, MPH</last_name>
    <phone>1-800-227-3422</phone>
    <email>gena.kantor@bsci.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

